Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome
Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome: Prospective, Multicentre, Randomized, Open-label, Blinded-endpoint Clinical Trial
Sponsor: Shandong First Medical University
A PHASE4 clinical study on Chronic Coronary Syndrome, this trial is actively recruiting participants. The trial is conducted by Shandong First Medical University and has accumulated 4 data snapshots since 2023. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jan 2024 — May 2024 [monthly]
Not Yet Recruiting PHASE4
First recorded
Dec 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shandong First Medical University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Binzhou, China , Chongqing, China , Dezhou, China , Feicheng, China , Jinan, China , Liaocheng, China , Linqing, China , Linyi, China , Longkou, China , Qingdao, China and 5 more locations